PURPOSE: Postoperative radiation therapy (RT) is recommended for patients with rhabdomyosarcoma having microscopic disease. Sometimes RT dose/volume is reduced or omitted in an attempt to avoid late effects, particularly in young children. We reviewed operative bed recurrences to determine if noncompliance with RT protocol guidelines influenced local-regional control. METHODS AND MATERIALS: All operative bed recurrences among 695 Group II rhabdomyosarcoma patients in Intergroup Rhabdomyosarcoma Study Group (IRS) I through IV were reviewed for deviation from RT protocol. Major/minor dose deviation was defined as >10% or 6-10% of the prescribed dose (40-60 Gy), respectively. Major/minor volume deviation was defined as tumor excluded from the RT field or treatment volume not covered by the specified margin (preoperative tumor volume and 2- to 5-cm margin), respectively. No RT was a major deviation. RESULTS: Forty-six of 83 (55%) patients with operative bed recurrences did not receive the intended RT (39 major and 7 minor deviations). RT omission was the most frequent RT protocol deviation (19/46, 41%), followed by dose (17/46, 37%), volume (9/46, 20%), and dose and volume deviation (1/46, 2%). Only 7 operative bed recurrences occurred in IRS IV (5% local-regional failure) with only 3 RT protocol deviations. Sixty-three (76%) patients with recurrence died of disease despite retrieval therapy, including 13 of 19 nonirradiated children. CONCLUSION: Over half of the operative bed recurrences were associated with noncompliance; omission of RT was the most common protocol deviation. Three fourths of children die when local-regional disease is not controlled, emphasizing the importance of RT in Group II rhabdomyosarcoma.
PURPOSE: Postoperative radiation therapy (RT) is recommended for patients with rhabdomyosarcoma having microscopic disease. Sometimes RT dose/volume is reduced or omitted in an attempt to avoid late effects, particularly in young children. We reviewed operative bed recurrences to determine if noncompliance with RT protocol guidelines influenced local-regional control. METHODS AND MATERIALS: All operative bed recurrences among 695 Group II rhabdomyosarcomapatients in Intergroup Rhabdomyosarcoma Study Group (IRS) I through IV were reviewed for deviation from RT protocol. Major/minor dose deviation was defined as >10% or 6-10% of the prescribed dose (40-60 Gy), respectively. Major/minor volume deviation was defined as tumor excluded from the RT field or treatment volume not covered by the specified margin (preoperative tumor volume and 2- to 5-cm margin), respectively. No RT was a major deviation. RESULTS: Forty-six of 83 (55%) patients with operative bed recurrences did not receive the intended RT (39 major and 7 minor deviations). RT omission was the most frequent RT protocol deviation (19/46, 41%), followed by dose (17/46, 37%), volume (9/46, 20%), and dose and volume deviation (1/46, 2%). Only 7 operative bed recurrences occurred in IRS IV (5% local-regional failure) with only 3 RT protocol deviations. Sixty-three (76%) patients with recurrence died of disease despite retrieval therapy, including 13 of 19 nonirradiated children. CONCLUSION: Over half of the operative bed recurrences were associated with noncompliance; omission of RT was the most common protocol deviation. Three fourths of children die when local-regional disease is not controlled, emphasizing the importance of RT in Group II rhabdomyosarcoma.
Authors: K S Baker; J R Anderson; M P Link; H E Grier; S J Qualman; H M Maurer; J C Breneman; E S Wiener; W M Crist Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: A S Pappo; J R Anderson; W M Crist; M D Wharam; P P Breitfeld; D Hawkins; R B Raney; R B Womer; D M Parham; S J Qualman; H E Grier Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544
Authors: L M Smith; J R Anderson; S J Qualman; W M Crist; C N Paidas; L A Teot; A S Pappo; M P Link; H E Grier; E S Wiener; J C Breneman; R B Raney; H M Maurer; S S Donaldson Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: Tobias M Dantonello; Christoph Int-Veen; Peter Winkler; Ivo Leuschner; Andreas Schuck; Bernhard F Schmidt; Helmut Lochbuehler; Sylvia Kirsch; Erika Hallmen; Iris Veit-Friedrich; Stefan S Bielack; Felix Niggli; Bernarda Kazanowska; Ruth Ladenstein; Thomas Wiebe; Thomas Klingebiel; Joern Treuner; Ewa Koscielniak Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann Journal: Cancer Date: 1993-03-01 Impact factor: 6.860
Authors: H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega Journal: Cancer Date: 1988-01-15 Impact factor: 6.860
Authors: S S Donaldson; M Torrey; M P Link; A Glicksman; L Gilula; F Laurie; J Manning; J Neff; W Reinus; E Thompson; J J Shuster Journal: Int J Radiat Oncol Biol Phys Date: 1998-08-01 Impact factor: 7.038
Authors: Chris Beltran; Renin Lukose; Bijumon Gangadharan; Ali Bani-Hashemi; Bruce A Faddegon Journal: J Appl Clin Med Phys Date: 2009-06-17 Impact factor: 2.102
Authors: Suman Malempati; David A Rodeberg; Sarah S Donaldson; Elizabeth R Lyden; James R Anderson; Douglas S Hawkins; Carola A S Arndt Journal: Cancer Date: 2011-01-24 Impact factor: 6.860
Authors: Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter Journal: J Natl Cancer Inst Date: 2013-03-06 Impact factor: 13.506
Authors: Julie A Bradley; Mark L Kayton; Yueh-Yun Chi; Douglas S Hawkins; Jing Tian; John Breneman; Suzanne L Wolden; David Walterhouse; David A Rodeberg; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-20 Impact factor: 7.038
Authors: John Breneman; Jane Meza; Sarah S Donaldson; R Beverly Raney; Suzanne Wolden; Jeff Michalski; Fran Laurie; David A Rodeberg; William Meyer; David Walterhouse; Douglas S Hawkins Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-19 Impact factor: 7.038
Authors: Jamie M Aye; Yueh-Yun Chi; Jing Tian; Erin R Rudzinski; Odion T Binitie; Roshni Dasgupta; Suzanne L Wolden; Douglas S Hawkins; Abha A Gupta Journal: Pediatr Blood Cancer Date: 2020-03-02 Impact factor: 3.167
Authors: David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt Journal: Int J Cancer Date: 2014-12-10 Impact factor: 7.396
Authors: Christopher G Willett; Jennifer Moughan; Elizabeth O'Meara; James M Galvin; Christopher H Crane; Kathryn Winter; Denise Manfredi; Tyvin A Rich; Rachel Rabinovitch; Robert Lustig; Mitchell Machtay; Walter J Curran Journal: Radiother Oncol Date: 2012-10-17 Impact factor: 6.280